Our present work demonstrated that ZY0511 possessed a strong anti‐HCC efficiency both in vitro and in vivo, exhibiting an anti‐HCC efficiency superior to other LSD1 inhibitors, such as GSK2879552 and ORY1001. The gene discussed is KDM1A; the disease is hepatocellular carcinoma.